BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
pharmaphorum16h
MSD joins PD-1/VEGF push in cancer with LaNova deal
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
BioNTech signs agreement to acquire Biotheus to enhance tumor treatment capabilities
BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a ...
Mena FN22h
BioNTech purchases Chinese biotechnology company to improve oncology strategy
The German firms is going to obtain the rights to Biotheus’ “investigational bispecific antibody” named the “BNT327/PM8002,” and use it in its oncology strategy. The advanced clinical asset focuses on ...